References
- Schuller Y, Hollak CE, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review. Orphanet J Rare Dis. 2015;10:783.
- Ciani O, Jommi C. The role of health technology assessment bodies in shaping drug development. Drug Des Devel Ther. 2014;8:2273–2281.
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
- Lakdawalla DN, Doshi JA, Garrison LPJ, et al. Defining elements of value in health care-a health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21(2):131–139.
- National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. Published October 2014. Last updated October 2020; 2020. Available from: https://www.nice.org.uk/process/pmg20/chapter/introduction.
- Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR good research practices task force report. Value Health. 2015;18(2):161–172.
- Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017. Available from: https://www.cadth.ca/sites/default/files/pdf/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf.
- The Pharmaceutical Benefits Advisory Committee. PBAC guidelines, section 3: economic evaluation; 2016. Available from: https://pbac.pbs.gov.au/section-3-economic-evaluation.html.
- Drummond MF. Challenges in the economic evaluation of orphan drugs. Eurohealth. 2008;14(2):16–17.
- Institute for Clinical and Economic Review. Assessing the effectiveness and value of drugs for rare conditions; 2017. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_Assessing-the-Value-of-Drugs-for-Rare-Conditions_051017-1.pdf.
- Picavet E, Cassiman D, Simoens S. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses. J Clin Pharm Ther. 2015;40(3):304–307.
- National Institute for Health and Care Excellence. Interim process and methods of the Highly Specialised Technologies Programme updated to reflect 2017 changes; 2017. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-highly-specialised-technologies-guidance/HST-interim-methods-process-guide-may-17.pdf.
- Taylor C, Jan S, Thompson K. Funding therapies for rare diseases: an ethical dilemma with a potential solution. Aust Health Rev. 2018;42(1):117–119.
- Institute for Clinical and Economic Review. Modifications to the ICER value assessment framework for treatments for ultra‐rare diseases; 2017. Available from: https://icer.org/wp-content/uploads/2020/10/ICER-Adaptations-of-Value-Framework-for-Rare-Diseases.pdf.
- Brown R, Ioannou P, Cadwell K. A review of six years of the NICE Highly Specialised Technology (HST) programme. Value Health. 2019;22:S860.
- Institute for Clinical and Economic Review. 2020-2023 Value Assessment Framework; 2020. Available from: https://icer.org/wp-content/uploads/2020/11/ICER_2020_2023_VAF_02032022.pdf.
- National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013; 2013. [cited 2019 September 19]. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.
- Cameron D, Ubels J, Norstrom F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action. 2018;11(1):1447828.
- Nanavaty M, Kaura S, Mwamburi M, et al. The use of incremental cost-effectiveness ratio thresholds in health technology assessment decisions; 2015. Available from: https://www.hmpgloballearningnetwork.com/site/jcp/article/use-incremental-cost-effectiveness-ratio-thresholds-health-technology-assessment-decisions.
- Cahill JR. Traditional cost-effectiveness formulas and precision medicines. Health Affairs. 2020 [cited Blog summarizing the limitations of cost-effectiveness analyses of treatments for rare, chronic diseases. p.]. Available from: 10.1377/forefront.20200527.292431
- Paulden M, O'Mahony JF, McCabe C. Discounting the recommendations of the second panel on cost-effectiveness in health and medicine. Pharmacoeconomics. 2017;35(1):5–13.
- Zorginstituut Nederland. Guideline for economic evaluations in healthcare; 2016. Available from: https://english.zorginstituutnederland.nl/publications/reports/2016/06/16/guideline-for-economic-evaluations-in-healthcare.
- HM Treasury. The green book: central government guidance on appraisal and evaluation. London; 2018.
- Solem CT, Vera-Llonch M, Liu S, et al. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes. 2016;14:63.
- IMS Institute for Healthcare Informatics. Price declines after branded medicines lost exclusivity in the U.S. 2016. [cited 2019 September 17]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/price-declines-after-branded-medicines-lose-exclusivity-in-the-us.pdf.
- Vondeling GT, Cao Q, Postma MJ, et al. The impact of patent expiry on drug prices: a systematic literature review. Appl Health Econ Health Policy. 2018;16(5):653–660.
- Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65–124.
- Mall MA, Mayer-Hamblett N, Rowe SM. Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications. Am J Respir Crit Care Med. 2020;201(10):1193–1208.
- Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry 2020 annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2021.
- Vertex Pharmaceuticals Incorporated. Trikafta® (elexacaftor/tezacaftor/ivacaftor) [package insert]. Boston, MA: Vertex Pharmaceuticals Incorporated; 2021.
- Vertex Pharmaceuticals (Ireland) Limited. Kaftrio® (elexacaftor/tezacaftor/ivacaftor) [summary of product characteristics]. Dublin, Ireland: Vertex Pharmaceuticals (Ireland) Limited; 2021.
- Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809–1819.
- Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940–1948.
- Barry PJ, Mall MA, Álvarez A, et al. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes. N Engl J Med. 2021;385(9):815–825.
- Daines CL, Tullis E, Costa S, et al. editors. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 96-week interim results from an open-label extension study. 35th Annual North American Cystic Fibrosis Conference (virtual); 2021.
- Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry 2015 annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2016.
- Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–689.
- Rubin JL, O'Callaghan L, Pelligra C, et al. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor. Ther Adv Respir Dis. 2019;13:1753466618820186.
- McGarry L, Lopez A, Chandler C, et al. Validation of modeled 5-year survival outcomes among patients with Cystic Fibrosis (CF) treated with the CF Transmembrane Conductance Regulator Modulator (CFTRm) ivacaftor using US CF Foundation Patient Registry (USCFFPR) data. Value Health. 2020;23(suppl 1):S8.
- Westra TA, Parouty M, Brouwer WB, et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health. 2012;15(3):562–567.
- Rogoza RM, Westra TA, Ferko N, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in The Netherlands. Vaccine. 2009;27(35):4776–4783.
- Wan X, Zhang Y, Tan C, et al. First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis. JAMA Oncol. 2019;5(4):491–496.
- Banken R, Rind D, Cramer G, et al. Voretigene neparvovec for biallelic RPE65-mediated retinal disease: effectiveness and value; 2018. Available from: https://icer.org/wp-content/uploads/2020/10/MWCEPAC_VORETIGENE_FINAL_EVIDENCE_REPORT_02142018.pdf.
- Tice JA, Kuntz KM, Wherry K, et al. Modulator treatments for cystic fibrosis: effectiveness and value; final evidence report and meeting summary; 2020. Available from: https://icer.org/wp-content/uploads/2020/08/ICER_CF_Final_Report_092320.pdf.
- Fajac I, Van Brunt K, Daines C, et al. Impact of elexacaftor/tezacaftor/ivacaftor triple combination therapy on health-related quality of life in people with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a phase 3 clinical study. J Cyst Fibros. 2020;19(suppl 2):S118–S119.
- Majoor C, Van Brunt K, Daines C, et al. Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) triple combination therapy on Health-Related Quality of Life (HRQoL) in People with Cystic Fibrosis (pwCF) homozygous for F508del (F/F): results from a phase 3 clinical study. J Cyst Fibros. 2020;19(suppl 2):S32.
- Acaster S, Mukuria C, Rowen D, et al. Development of the cystic fibrosis questionnaire-revised preference based scoring algorithm. Pediatr Pulmonol. 2019;758:S443.
- Whiting P, Al M, Burgers L, et al. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 2014;18(18):106.
- Davis S. Assessing technologies that are not cost-effective at a zero price. London: National Institute for Health and Care Excellence (NICE): NICE Decision Support Unit Methods Development; 2014.
- Toporek A, Merlo CA, West NE. Use of chronic maintenance therapies for cystic fibrosis in patients on elexacaftor, tezacaftor, ivacaftor at a single center. Am J Respir Crit Care Med. 2021;203:A2024.
- Brown C, Powers C, Teibel H, et al. editors. Patients on elexacaftor/tezacaftor/ivacaftor decrease chronic daily therapy within two months of initiation. North America Cystic Fibrosis Conference (virtual); 2020.
- Wallner K, Shapiro AM, Senior PA, et al. Cost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitus. BMC Endocr Disord. 2016;16:17.
- Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007;151(2):134–139.e1.
- Konstan MW, Wagener JS, VanDevanter DR, et al. Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. J Cyst Fibros. 2012;11(5):405–411.
- Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax. 2007;62(4):360–367.
- Truven Health Analytics. Red Book Online 2020. [cited 2019 January 3]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian.
- Hu X, Sawicki G, Bonafede M, et al. An early view of characteristics and treatment patterns of patients initiated on tezacaftor/ivacaftor in the United States: an administrative claims data analysis. Manag Care Spec Pharm. 2019;25(suppl):S71.
- Vertex Pharmaceuticals Incorporated. Trikafta® (elexacaftor/tezacaftor/ivacaftor) [package insert]. Boston MA: Vertex Pharmaceuticals Incorporated; 2019.
- Centers for Medicare and Medicaid Services. Episode-of-Care Payment 2019. Available from: https://www.cmshospitalchartbook.com/visualization/2019/episode-care-payment.
- McGarry L, Lopez A, Booth J, et al. Application of the CFQ-R-8D to estimate utility benefit of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis (CF). Value Health. 2020;23(suppl 2):S731–S732.